Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg
capsules in achieving clinical improvement of COVID-19 symptoms. A secondary goal of this
study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19
infection.